Esophageal Squamous Cell Carcinoma Clinical Trial
Official title:
The THINKER Study: A Pilot for a Case-Control of Esophageal Squamous Cell Carcinoma in Western Kenya
| Verified date | April 2020 |
| Source | National Institutes of Health Clinical Center (CC) |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Background:
- Esophageal cancer is the sixth leading cause of cancer deaths worldwide. Two primary
cell types, squamous cell carcinoma and adenocarcinoma, account for most cases. Of the
two, esophageal squamous cell carcinoma (ESCC) accounts for more than 80 percent of all
deaths from esophageal cancer. Many cases occur in certain areas with defined geographic
boundaries, including parts of Kenya.
- Studies of ESCC in developed countries (such as the United States) suggest that heavy
tobacco and alcohol use, poor diet, and low socioeconomic status are the primary risk
factors. Males and African Americans are also at higher risk. However, these risk
factors do not fully explain the prevalence of cases in several of the identified
geographic areas.
- ESCC is the most common cancer seen at Tenwek Hospital in western Kenya, and a notable
number of patients are 30 years of age or younger.
Objectives:
- To test the feasibility of a new protocol by recruiting visitors to Tenwek Hospital and
volunteers from the general population for study purposes.
- To use the new protocol to obtain blood and urine samples from ESCC cases in Tenwek
Hospital and from nonpatient volunteers.
Eligibility:
- Hospital patients and volunteers who live within 50 kilometers of Tenwek Hospital in
western Kenya.
Design:
- All participants will complete a questionnaire and provide blood and urine samples for
testing.
- The questionnaire will include questions about individual and family medical
history, living conditions, lifestyle, habits, and diet.
- Blood and urine samples will be collected from all participants after the
questionnaire.
- Biological samples will be shipped to the United States for further testing.
- Treatment will not be offered as part of this study.
| Status | Completed |
| Enrollment | 372 |
| Est. completion date | April 20, 2020 |
| Est. primary completion date | April 20, 2020 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 7 Years to 99 Years |
| Eligibility |
- Cases: INCLUSION CRITERIA: 1. Consent to participate in the study 2. Pathologically diagnosed with esophageal squamous cell carcinoma at Tenwek Hospital, Bomet Kenya 3. Primary residence within 50 kilometers of Tenwek Hospital, Bomet Kenya EXCLUSION CRITERIA: 1. Does not consent to participation in the study 2. Mental impairment that precludes consenting to or completing the study questionnaire Controls: INCLUSION CRITERIA: 1. Consent to participation in the study 2. No previous history of malignancy 3. Primary residence within 50 kilometers of Tenwek Hospital, Bomet Kenya EXCLUSION CRITERIA: 1. Does not consent to participation in the study 2. Mental impairment that precludes consenting to or completing the study questionnaire |
| Country | Name | City | State |
|---|---|---|---|
| Kenya | Tenwek Hospital | Bornet |
| Lead Sponsor | Collaborator |
|---|---|
| National Cancer Institute (NCI) |
Kenya,
Dawsey SP, Tonui S, Parker RK, Fitzwater JW, Dawsey SM, White RE, Abnet CC. Esophageal cancer in young people: a case series of 109 cases and review of the literature. PLoS One. 2010 Nov 22;5(11):e14080. doi: 10.1371/journal.pone.0014080. Review. — View Citation
Nieminen MT, Novak-Frazer L, Collins R, Dawsey SP, Dawsey SM, Abnet CC, White RE, Freedman ND, Mwachiro M, Bowyer P, Salaspuro M, Rautemaa R. Alcohol and acetaldehyde in African fermented milk mursik--a possible etiologic factor for high incidence of esophageal cancer in western Kenya. Cancer Epidemiol Biomarkers Prev. 2013 Jan;22(1):69-75. doi: 10.1158/1055-9965.EPI-12-0908. Epub 2012 Nov 15. — View Citation
White RE, Abnet CC, Mungatana CK, Dawsey SM. Oesophageal cancer: a common malignancy in young people of Bomet District, Kenya. Lancet. 2002 Aug 10;360(9331):462-3. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Esophageal squamous cell carcinoma | determined by pathology results from endoscopic biopsy | At diagnosis |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06056336 -
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Suspended |
NCT04084158 -
A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.
|
Phase 2 | |
| Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT05561699 -
Sequential Preoperative Penpulimab Combined With Chemoradiotherapy(CRT) for Locally Advanced Esophageal Squamous Cell Cancer
|
N/A | |
| Active, not recruiting |
NCT04543617 -
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
|
Phase 3 | |
| Recruiting |
NCT06190782 -
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
|
Phase 3 | |
| Completed |
NCT05557955 -
Identification of Breath Biomarkers in Esophageal Cancer
|
||
| Recruiting |
NCT04045496 -
A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Not yet recruiting |
NCT03766178 -
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02913066 -
S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02399306 -
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
|
Phase 3 | |
| Completed |
NCT01605305 -
Study on FOLFOX6 as First-line Therapy to Treat Recurrent or Metastatic Esophageal Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05552651 -
Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05520619 -
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)
|
Phase 2 | |
| Terminated |
NCT03251417 -
Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05990231 -
Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT04644250 -
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Completed |
NCT02916511 -
Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Terminated |
NCT04032704 -
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
|
Phase 2 |